Cargando…
The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
Immune checkpoint inhibitors have made remarkable breakthroughs in the treatment of lung cancer, bringing significant survival benefits to the patients. A number of adverse events aggravated by immunotherapy in patients with pre-existing autoimmune diseases have been reported in the past, especially...
Autores principales: | Gao, Zhiru, Xu, Yinghui, Zu, Jianjiao, Wang, Xu, Sun, Chao, Qiu, Shi, Guo, Ye, Ma, Kewei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424493/ https://www.ncbi.nlm.nih.gov/pubmed/36052082 http://dx.doi.org/10.3389/fimmu.2022.946829 |
Ejemplares similares
-
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo
por: Agarwal, Priti, et al.
Publicado: (2014) -
Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011) -
PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin
por: Miao, Xiao, et al.
Publicado: (2018) -
CCL22 to activate Treg migration and suppress depigmentation in vitiligo
por: Eby, Jonathan M., et al.
Publicado: (2015) -
Psychosocial and quality-of-life factors associated with depigmentation therapy for vitiligo
por: Cadmus, Simi D., et al.
Publicado: (2023)